Understanding how PARP inhibitors affect bone marrow health
Mechanisms of Parp inhibitor-induced bone marrow toxicities
This study is looking at how a type of cancer drug called PARP inhibitors affects bone marrow health and blood cell production, to help identify which patients might be more at risk for side effects based on their genetics.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Wisconsin-Madison NIH-funded |
| Lab location | 1 site (Madison, United States) |
| Project ID | NIH-11082346 on NIH RePORTER |
What this research studies
This research investigates the effects of PARP inhibitors, a class of cancer drugs, on bone marrow function and health. It aims to understand how these drugs, which are effective in treating various cancers, may also cause serious side effects in normal blood cells. By studying the mechanisms behind these adverse effects, the research seeks to identify which patients might be more vulnerable due to genetic factors. The approach involves analyzing blood cell formation and the response of bone marrow cells to these drugs.
Who could benefit from this research
Good fit: Ideal candidates for this research include cancer patients who are being treated with PARP inhibitors and those with specific genetic mutations affecting their bone marrow.
Not a fit: Patients who are not undergoing treatment with PARP inhibitors or do not have blood-related conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to safer cancer treatments by minimizing harmful side effects associated with PARP inhibitors.
How similar studies have performed: Previous research has shown that understanding drug interactions with bone marrow can lead to improved safety profiles for cancer treatments, indicating potential for success in this area.
Where this research is happening
Madison, United States
- University of Wisconsin-Madison — Madison, United States (Active)
Researchers
- Principal investigator: Churpek, Jane Ellen — University of Wisconsin-Madison
- Study coordinator: Churpek, Jane Ellen
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.